Journal of Nihon University Medical Association
Online ISSN : 1884-0779
Print ISSN : 0029-0424
ISSN-L : 0029-0424
Casel Reports:
Pathological Complete Response of HER2-Positive Local Advanced Breast Cancer to Trastuzumab, Pertuzumab and Docetaxel Therapy
Yuichi Ueda, Kenichi Sakurai, Katsuhisa Enomoto, Mayumi Tani, Sadao Amano
Author information
Keywords: pertuzumab, neoadjuvant chemotherapy, HER2 positive breast cancer, pathological complete response
JOURNAL FREE ACCESS

2015 Volume 74 Issue 3 Pages 117-120

Details
Download PDF (1557K)
Download citation RIS

(compatible with EndNote, Reference Manager, ProCite, RefWorks)

BIB TEX

(compatible with BibDesk, LaTeX)

Text
How to download citation
Contact us
Abstract
Pertuzumab was approved as an anti-HER2 agent in Japan in June 2013. In an overseas clinical trial, pertuzumab combination therapy had significantly better efficacy for time to progression and overall survival in HER2-positive metastatic breast cancer. Here, we describe a case of HER2-positive local advanced breast cancer that showed a pathological complete response to therapy with trastuzumab, pertuzumab and docetaxel.
Content from these authors
© 2015 The Nihon University Medical Association
Previous article Next article
Favorites & Alerts

Recently viewed articles
Share this page
feedback
 Top